Clinical Research Directory

Inclusion Criteria 1. Age≥18 years as of the screening date; 2. Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date; 3. Prescribed Evolocumab at physician's discretion; 4. Signed informed consent. Exclusion Criteria: 1. Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.; 2. Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis); 3. Silent cerebral infarction without signs and symptoms; 4. Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date; 5. Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date; 6. Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date; 7. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders; 8. Refusal to participate in the enrollment survey.